Galderma Group AG
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 123
- Registration Number
- NCT05089708
- Locations
- 🇺🇸
Galderma Investigational Site #8636, Fountain Valley, California, United States
🇺🇸Galderma Investigational Site #8224, Fremont, California, United States
🇺🇸Galderma Investigational Site #8358, San Diego, California, United States
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 250
- Registration Number
- NCT05089357
- Locations
- 🇨🇳
Hangzhou Yanshuyuerong medical cosmetology clinic, Hangzhou, Zhejiang, China
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
- Conditions
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 258
- Registration Number
- NCT05075408
- Locations
- 🇺🇸
Galderma Investigational Site 9989, Bakersfield, California, United States
🇺🇸Galderma Investigational Site 9991, Glendale, California, United States
🇺🇸Galderma Investigational Site 7018, Glendale, California, United States
Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite
- Conditions
- Cellulite
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 29
- Registration Number
- NCT05064761
- Locations
- 🇨🇦
Galderma Research Site, Vancouver, British Columbia, Canada
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
- Conditions
- Moderate-to-severe Atopic Dermatitis
- Interventions
- Drug: CD14152 placebo
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT05056779
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 34
- Registration Number
- NCT05052983
- Locations
- 🇺🇸
Galderma Investigational Site 8521, Saint Joseph, Missouri, United States
🇦🇹Galderma Investigational Site 5471, Graz, Austria
🇦🇹Galderma Investigational Site 6158, Vienna, Austria
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
- Conditions
- Xerosis Cutis
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT05046015
- Locations
- 🇩🇪
Charité Universitatsmedizin Berlin, Berlin, Germany
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 105
- Registration Number
- NCT04921345
- Locations
- 🇺🇸
Galderma Investigational Site #8636, Fountain Valley, California, United States
🇺🇸Galderma Investigational Site #9937, San Diego, California, United States
🇺🇸Galderma Investigational Site #9930, Vista, California, United States
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 121
- Registration Number
- NCT04856904
- Locations
- 🇺🇸
Galderma Investigational Site #8873, Scottsdale, Arizona, United States
🇺🇸Galderma Investigational Site #8447, Fort Smith, Arkansas, United States
🇺🇸Galderma Investigational Site #8608, Santa Monica, California, United States
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
- Conditions
- Wrinkle
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 192
- Registration Number
- NCT04717934
- Locations
- 🇺🇸
Galderma Research Site, Mequon, Wisconsin, United States